| Study ID | Studied Indication or Disease | Phase | Study Title | Synopsis |
|---|
| 20120216 | Adult subjects with Relapsed/Refractory (R/R) Philadelphia Chromosome Positive (Ph+) B-precursor Acute Lymphoblastic Leukemia (ALL) | 2 | A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE; Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)
|  |
| 20130265 | Adult and pediatric subjects with relapsed/refractory (R/R) B-precursor ALL | 1b/2 | A Phase 1b/2 Study of Blinatumomab in Japanese Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study) | |
| 20130320 | Relapsed/Refractory B-Precursor ALL | 4 | An Open-label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
| |
| MT103-104 | CANCER - LIQUID TUMORS | 1 |
An Open-Label, Multi-Center Phase 1 Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-Cell Engager MT103 in Subjects With Relapsed Non-Hodgkin’s Lymphoma (NHL)
| |
| MT103-202 | CANCER - LIQUID TUMORS | 2 |
An Open-label, Multicenter Phase 2 Study to Investigate the Efficacy, Safety, and Tolerability of the Bi-specific T-cell Engager (BiTE®) MT103 in Patients with Minimal Residual Disease (MRD) of Positive B-precursor Acute Lymphoblastic Leukemia (ALL)
| |
| MT103-203 | CANCER - LIQUID TUMORS | 2 |
A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BITE® Antibody Blinatumomab in Adult Subjects with Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
| |
| MT103-205 | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | 1/2 | A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE„µ Antibody Blinatumomab (MT103) in
Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | |
| MT103-206 | CANCER - LIQUID TUMORS | 2 |
An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
| |
| MT103-208 | CANCER - LIQUID TUMORS | 2 |
An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
| |
| MT103-211 | CANCER - LIQUID TUMORS | 2 |
An Open-label, Multicenter, Phase 2 Study to Evaluate Efficacy and Safety of the Bi-specific T cell Engager (BiTE®) Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
| |
| MT103-311 | Adult Subjects with Relapsed/Refractory (R/R) B-precursor ALL | 3 | A Phase 3, Randomized, Open-label Study Investigating the Efficacy of the BiTE; Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
| |
Amgen Worldwide